Management of peritoneal metastases from colorectal cancer and small bowel adenocarcinoma in patients with inflammatory bowel disease

Table 2 Postoperative outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (cytoreductive surgery with hyperthermic intraperitoneal chemotherapy) in patients with and without inflammatory bowel disease with peritoneal metastases

Metric	Ben-Yaacov et al[45], 2024		Hammoudi et al[21], 2018
	IBD cohort (n = 10)	Non-IBD cohort (n = 222)
Overall complications1	60.3% (P = 0.744)5	60.3% (P = 0.444)	54.5% grade 3-4
Reoperation rate2	27%		Not separately tabulated
ICU/hospital stay3	No significant difference		Median not reported
30-day mortality4	0%		0%

¹Overall complications: Any postoperative adverse event within 30 days, graded by Clavien-Dindo. Major complications: Clavien-Dindo grade III-IV events requiring surgical, endoscopic, or radiologic intervention (grade III) or life-threatening complications requiring intensive care unit management (grade IV).

²Reoperation rate: Percentage of patients requiring return to the operating room within 30 days.

³When median intensive care unit/hospital stays are not reported, indicate “not reported” and consider including these metrics in future data collection for completeness.

⁴30-day mortality: Perioperative death within 30 days post-surgery.

⁵P values (where reported) compared inflammatory bowel disease vs non-inflammatory bowel disease; P < 0.05 considered significant. Non-significant P values in small samples may reflect limited power.

ICU: Intensive care unit; IBD: Inflammatory bowel disease.